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Inherited Human Caspase 10 Mutations Underlie
Defective Lymphocyte and Dendritic Cell Apoptosis
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Sheridan et al., 1997; Thomas and Hersey, 1998). Recent
experiments suggest that the fate of specialized anti-
gen-presenting cells is also regulated during immune
responses. Ingulli et al. (1997) have shown that antigen-
bearing dendritic cells directly interact with antigen-spe-
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‖Laboratory of Pathology We and others have identified the autoimmune lym-
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National Institutes of Health ease of lymphocyte homeostasis and defective apopto-
Bethesda, Maryland 20892 sis (Fisher et al., 1995; Rieux-Laucat et al., 1995; Drappa
et al., 1996; Bettinardi et al., 1997; Sneller et al., 1997;
Kasahara et al., 1998). ALPS patients manifest lympho-
Summary cytosis, including an otherwise rare population of
CD42CD82 T cells, and autoimmune disorders. In ALPS
Caspases are cysteine proteases that mediate pro- type Ia, this phenotype is associated with inherited mu-
grammed cell death in phylogenetically diverse multi- tations in the APT1 gene on chromosome 10q24.1 en-
cellular organisms. We report here two kindreds with coding Fas (Straus et al., 1999). In ALPS type Ib, sys-
autoimmune lymphoproliferative syndrome (ALPS) type temic lupus erythematosus and lymphadenopathy are
II, characterized by abnormal lymphocyte and den- associated with inherited mutations in the Fas ligand
dritic cell homeostasis and immune regulatory de- (FasL) gene on chromosome 1q23 (Wu et al., 1996). The
fects, that harbor independent missense mutations in lpr and gld alleles cause similar diseases in mice due
Caspase 10. These encode amino acid substitutions to homozygous recessive mutations in the Fas and FasL
that decrease caspase activity and interfere with death genes, respectively (Watanabe-Fukunaga et al., 1992;
receptor±induced apoptosis, particularly that stimu- Lynch et al., 1994; Takahashi et al., 1994). ALPS type II
lated by Fas ligand and TRAIL. These results provide is manifested by a related clinical phenotype and apo-
evidence that inherited nonlethal caspase abnormali- ptosis defects in the absence of either Fas or FasL muta-
ties cause pleiotropic apoptosis defects underlying tions (Dianzani et al., 1997; Sneller et al., 1997). The
autoimmunity in ALPS type II. molecular basis for ALPS type II has not been previously
identified.
A key cell death molecule, CED-3, in C. elegans isIntroduction
the prototype of a new family of cysteinyl-aspartate-
requiring proteinases, or caspases, that play a crucialA dynamic balance in the quantity and activation state
role in mammalian apoptosis (Yuan et al., 1993; Horvitzof cells participating in immune responses is essential
et al., 1994; Alnemri et al., 1996; Nicholson and Thorn-for achieving appropriate proliferative and effector re-
berry, 1997). Caspases are synthesized as zymogenssponses to antigens while avoiding autoimmunity (for
that are proteolytically activated either by autoprocess-reviews, Abbas, 1996; Lenardo, 1997). This has been
ing or via other caspases. Caspase 8 (CASP8) occupiesbest defined for lymphocytes for which removal of T or
a proximal position in Fas and TNFR signaling becauseB cells by antigen receptor engagement or the loss of
it contains two death effector domains (DEDs) in itstrophic stimuli leads to apoptosis during and after pe-
N-terminal prodomain. The DEDs allow CASP8 to inter-ripheral immune responses, thereby allowing feedback
act with the DED of Fas-associated protein with a deathor ªpropriocidalº regulation (Thompson, 1995; Lenardo,
domain (FADD)/MORT1. Homotypic interaction of the1996). Antigen-provoked death of lymphocytes is medi-
death domains in FADD and death receptors thus allowsated by Fas (CD95/APO-1), tumor necrosis factor recep-
CASP8 to be recruited into the death-inducing signalingtor (TNFR), and related molecules (Russell and Wang,
complex (Boldin et al., 1996; Muzio et al., 1996; Juo et1993; Zheng et al., 1995; Chinnaiyan and Dixit, 1997).
al., 1998). Deficiency in CASP8 causes prenatal mortalityOther death ligands such as TRAIL and its corresponding
and a loss of TNF- and Fas-induced apoptosis in micedeath receptors DR4 and DR5 are expressed in immune
cells, but their physiological functions are not well un- (Varfolomeev et al., 1998). Caspase 10/Mch4/FLICE2
derstood (Wiley et al., 1995; Marsters et al., 1996; Pitti (CASP10) is a novel caspase homologous to CASP8
et al., 1996; MacFarlane et al., 1997; Pan et al., 1997; and its gene linked to the CASP8 gene at the human
chromosome locus 2q23 (Fernandes-Alnemri et al.,
1996; Vincenz and Dixit, 1997). CASP10 induces apo-# To whom correspondence should be addressed (e-mail: lenardo@
nih.gov). ptosis after transfection into MCF-7 cells (Vincenz and
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Dixit, 1997), but its physiological role is unknown. More-
over, the participation of individual caspases in abnor-
malities of lymphocyte homeostasis and autoimmunity
has not been defined.
Since the initial description of defective lymphocyte
apoptosis associated with Fas mutations, we have ex-
amined 68 kindreds affected with various autoimmune
and lymphoproliferative abnormalities, most of which
prove to be ALPS type 1a. Here, we describe two ALPS
type II families with autoimmunity and pleiotropic apo-
ptosis defects in multiple pathways, but no molecular
abnormalities in Fas, FasL, TNFR1, TNFR2, FADD, or
CASP8. Rather, we found distinct inherited amino acid
substitutions in CASP10 in each family that resulted in
decreased enzyme activity and diminished apoptosis
by multiple death receptors. In contrast to Fas mutations
leading to ALPS type I, these CASP10 defects underlie
a unique disorder of dendritic cell and lymphocyte ho-
meostasis.
Results
Clinical Features
The proband in family 11 is an 11-year-old African Ameri-
can female first evaluated at the NIH in 1992. At one
year of age, she developed prominent nonmalignant ad-
Figure 1. Lymphocyte Apoptosis Assays
enopathy, hepatosplenomegaly, and Coombs-positive
Apoptosis of PBLs were induced by 1 mg/ml plate-bound 64.1 (Anti-
hemolytic anemia. She exhibited a wide-ranging loss of CD3), 1 mg/ml CH11 (Anti-Fas), or 1 mg/ml TRAIL at 378C for 24 hr,
self-tolerance involving hypergammaglobulinemia with and percent cell loss was analyzed as described (Fisher et al., 1995).
multiple autoantibodies, such as anti-erythrocyte, anti-
RNP, anti-SM, anti-SSB, and rheumatoid factor as well
T lymphocytes (PBL) in kindreds 11 and 36. In patientas anti-Factor VIII antibody, which caused a severe clot-
(Pt) 11 and, to a lesser extent, her mother, apoptosisting disorder. She had massive accumulation of single-
induced by TCR cross-linking and Fas cross-linking waspositive T cells and B cells, indicating loss of lymphocyte
decreased (Figure 1). We also examined apoptosis re-homeostasis. Also, 42% of her peripheral lymphocytes
sponses to a trimeric form of the TRAIL death-inducingwere the normally rare (,1%) CD42CD82ab T cells,
ligand (Walczak et al., 1999) and found defects in Pt 11which are increased in ALPS type I and in murine lpr
and her mother's lymphocytes, but not in ALPS type Idisease but usually not to this degree. The patient's
patients (Figure 1 and data not shown). No apoptosismother exhibited high levels of autoantibodies to nu-
defects were found in the father and sisters of Pt 11clear antigens and defective lymphocyte apoptosis (see
(Figure 1). Pt 36 also exhibited abnormal apoptosis re-below), both of which are features of ALPS. The patient's
sponses to TCR, Fas, or TRAIL stimulation, while hisfather and two sisters are healthy.
parents exhibited modest but significant defects. FlowThe proband of family 36 is a 10-year-old Ashkenazi
cytometry showed that Fas expression as well as apo-Jewish male recently evaluated at the NIH. Adenopathy
ptosis in response to staurosporine or lymphokine with-began at 11 months followed by bouts of prolonged
drawal was normal in Pt 11 and Pt 36 (data not shown).fever, splenomegaly, elevated sedimentation rate, ane-
These data suggested that Pt 11 might have inheritedmia, and reticulocytosis. At age 3, he had noninfectious,
a novel selective apoptosis defect from her mother in alymphocytic meningitis followed by optic neuritis indi-
heterozygous dominant fashion. By contrast, a putativecating a pattern of disparate inflammatory conditions.
genetic defect in Pt 36 would either have homozygousAt his recent evaluation, he exhibited adenopathy and
inheritance or have arisen de novo. Moreover, the apo-splenomegaly. Autoantibodies were not detected, but
ptosis defects in these families, unlike that in ALPS typelymphocyte phenotyping showed a dramatic T and B
I, affect death receptors in addition to Fas.lymphocytosis and increased CD42/CD82 T cells, espe-
cially a striking increase in gd CD42/CD82 T cells. Both
parents were clinically normal. Thus, despite normal Fas Identification of CASP10 Mutations
and FasL, both families manifested a loss of lymphoid To identify the molecular defect in Pt 11 and her mother,
homeostasis accompanied by autoimmune and inflam- we examined candidate genes. Single-stranded confor-
matory conditions. mational polymorphism (SSCP) analysis and sequenc-
ing of cDNAs revealed no mutations in the coding se-
quences of Fas, FasL, TNFR I (p55), FADD/MORT1,Lymphocyte Apoptosis Defects in ALPS Type II
In ALPS type I, T cell apoptosis induced by Fas or TCR TRADD, RIP, CASP7, CASP8, or CASP9 (data not
shown). However, we found a CASP10 mutation in Ptcross-linking is abnormal (Fisher et al., 1995). We there-
fore examined apoptosis in activated peripheral blood 11 that was a C to T transition predicted to replace a
CASP10 Mutations in ALPS Type II
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Figure 2. Sequences of CASP10
(A) Wild-type and Pt 11 mutant cDNA clones
(left); family 11 genomic DNA (right).
(B) Wild-type and Pt 36 mutant cDNA clones
(left); family 36 genomic DNA (right).
(C)The asterisk indicates the ªQACQGº active
site.
leucine by phenylalanine in the p17 subunit of the prote- downstream of the QACQG active site in the p17 subunit
of the CASP10 gene (Figure 2B). This mutation occurredase (Figure 2 and data not shown). In addition to the
previously described CASP10 cDNA (Fernandes-Alnemri in cDNAs of both isoforms of CASP10. In contrast to Pt
11, no wild-type allele was detected in Pt 36, suggestinget al., 1996), we also detected a longer cDNA isoform
(CASP10L). The CASP10L isoform encoded an insertion that the mutant allele is homozygous (Figure 2B). This
was confirmed by genomic DNA sequencing (Figure 2B).of 43 amino acids at the end of the prodomain identical
to the prodomain of FLICE2, but its C terminus was the Examination of the genomic DNA of both parents re-
vealed that each was heterozygous for the mutant allele,same as the short CASP10 isoform (Vincenz and Dixit,
1997). The two isoforms were expressed equally. Ap- indicating that the child had indeed inherited a mutant
CASP10 allele from each parent. No other nucleotideproximately 50% of CASP10 cDNAs (of either isoform)
were mutant, implying heterozygosity. This was con- changes were found in the CASP10 gene in Pt 36 or his
parents.firmed by direct sequencing of genomic DNA, which
revealed the wild-type C and mutant T nucleotides at To rule out the possibility that the mutations in Pt 11
and Pt 36 represented common genetic polymorphisms,the same position (Figure 2A). Genomic DNA sequencing
in the parents revealed that the father of Pt 11 and two we analyzed their frequency in the general population
and determined their effects on caspase function. Thesisters carried only wild-type alleles, but her mother
harbored both mutant and wild-type alleles (Figure 2A Pt 11 mutation destroyed a Stu I restriction site which
we used to determine that 100 unrelated normal donorand data not shown). Thus, the mutant CASP10 allele
in Pt 11 was inherited from her mother. No other base DNA samples, comprising 200 chromosomes, did not
harbor this nucleotide change (data not shown). SSCPchange in the coding or splicing sequences of CASP10
was found. analysis did not detect the Pt 36 mutation in 120 genomic
DNA samples (240 alleles) from healthy unrelated con-In Pt 36, SSCP screening followed by sequencing of
cDNA clones revealed a G to A transition predicted to trols of varied ethnicity and 100 unrelated Ashkenazi
Jewish genomic DNA samples (200 alleles) (data notcause a valine to isoleucine change seven amino acids
Cell
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Figure 3. Defective Apoptotic Activities of Mutant CASP10
(A) HeLa cells were transfected with 2 mg CASP10 plasmid or vector only in the presence of 0.6 mg b-gal construct DNA. Cells were fixed
and stained with X-gal 24 hr after transfection.
(B and C) Quantitation of apoptotic HeLa or MCF-7 cells after transfection with 2 mg wild-type or mutant CASP10 plasmids or vector only in
the presence of 0.6 mg b-gal construct.
shown). The CASP10 mutations have not been found in Quantitative analysis was performed with the bacteri-
ally expressed CASP10 protease domain of Pt 11 fusedany ALPS type I patient or family member. Our screening
did uncover one common polymorphic variant of CASP10 to glutathione S-transferase (GST). The wild-type CASP10
efficiently cleaved DEVD-AMC and to a lesser extent(nucleotide A1208→G in the p12 subunit), which was
observed in 5% of normal controls and had no effect YVAD-MCA, but the Pt 11 mutant protein failed to do
on apoptotic function of CASP10 (data not shown). so (Figure 4A). We also examined autoprocessing and
Therefore, the CASP10 mutations in families 11 and 36 found that the wild-type 55 kDa GST fusion protein was
are not common genetic polymorphisms. cleaved to the 43 kDa active form by 15 min, whereas
the mutant protein showed only 50% cleavage at 3 hr
(Figure 4B). To distinguish between decreased intrinsicAbrogation of Apoptosis Activities
catalytic ability versus the failure of the mutant proteinby CASP10 Mutations
to be recognized as an autosubstrate, equivalent amountsThe cooccurrence of CASP10 mutations with apoptosis
of cleaved wild-type and mutant GST-CASP10 were as-defects and immunological abnormalities in Pt 11 and
sayed using a DEVD peptide substrate (Figure 4C). WePt 36 suggested, but did not prove, that the mutations
observed significantly reduced catalytic activity by thecontributed to these abnormalities. We therefore deter-
mutant enzyme, with a Km of 709 6 14.4 mM comparedmined whether the altered forms of CASP10 were func-
to a Km of 71 6 12.9 mM for the wild-type CASP10.tionally defective. Expression constructs of both the
long and short isoforms of the wild-type or the CASP10
mutants were transfected into HeLa or MCF-7 cells to-
Dominant-Negative Interactiongether with a b-gal reporter construct. The cells were
of the Mutated CASP10stained with X-gal, and cell death was assessed in the
To explore how the heterozygous allele in Pt 11 and herblue transfected cells (Figure 3). Either isoform of wild-
mother could impair apoptosis, we coexpressed Fastype CASP10 induced significant cell death, but neither
with either the long or short isoform of the Pt 11 mutantisoform of the Pt 11 had detectable apoptotic activity
CASP10 in 293 cells and found that apoptosis was sup-in this assay (Figures 3A and 3B). Similar analyses of the
pressed (Figure 5). We also coexpressed the CASP10Pt 36 CASP10 revealed a significant, albeit less severe,
defect in apoptosis function (Figures 3A and 3C). mutants with the TNFR1, DR3, DR4 (TRAIL-R1), and DR5
CASP10 Mutations in ALPS Type II
51
staurosporine (data not shown). Hence, the abnormal
CASP10 protein specifically interfered with multiple
death receptor pathways and not other apoptosis
pathways.
To explain the interference in death pathways caused
by the heterozygous CASP10 mutation in Pt 11, we hy-
pothesized that CASP10 might be recruited into death-
inducing signaling complexes (DISCs) with the cyto-
plasmic tails of death receptors. Because the prodomain
of CASP10 is structurally similar to that of CASP8, it is
possible that the mutant CASP10 can be recruited along
with wild-type CASP8 or CASP10 into the DISC. We first
tested the interactions of CASP10 with CASP8 or FADD
using the yeast two-hybrid system and found that the
long and short isoforms of either full-length CASP10 or
the CASP10 DEDs interact with both CASP8 and FADD
(data not shown). To directly test recruitment of Pt 11
mutant CASP10 into the DISC, we cotransfected Fas,
FADD, and both isoforms of mutant CASP10 into 293T
cells. Both FADD and the mutant CASP10 were readily
detected in coprecipitates with Fas, consistent with pre-
vious observations on FLICE2 (Figure 6; Vincenz and
Dixit, 1997). Importantly, the mutant CASP10 isoforms
are corecruited with endogenous CASP8 (Figure 6, bot-
tom). This suggests the possibility that the mutant
CASP10 from Pt 11, which inefficiently autoprocesses,
is recruited into the DISC together with CASP8 and could
thereby block caspase activation in a dominant fashion.
Resistance of Dendritic Cells to
TRAIL-Mediated Apoptosis
To explain the multiple autoimmune and inflammatory
disorders in ALPS type II, we also examined how the Pt
11 and Pt 36 CASP10 mutations affect death receptor±
associated apoptosis in antigen-presenting cells. Previ-
ous observations of T cell±dependent turnover of den-
dritic cells suggested that dendritic cells may undergo
apoptosis triggered by death receptors (Ingulli et al.,
1997). Dendritic cells were derived from peripheral blood
using a previously described procedure (Sallusto and
Lanzavecchia, 1994), and we first asked whether acti-
vated T cells could foster their death in vitro. Using
Figure 4. Decreased Ezymatic Activity of Pt11 CASP10 dendritic cells as chromium-labeled targets, we found
(A) Bacterially expressed GST-CASP10 attached to glutathione-con- that activated autologous CD41 T cells killed CD831
jugated beads was used for a cleavage assay with 50 mM DEVD-
dendritic cells following TCR engagement (Figures 7AAMC (circles) or YVAD-AMC (triangles) substrate for 0, 1, 2, and 3
and 7B). The T cell±dependent lysis of dendritic cellshr, and the release of AMC was quantitated by a fluorospectrophoto-
was suppressed by DR5-Fc (TRAIL-R2-Fc), whereasmeter (open symbols, wild type; filled symbols, mutant).
(B) GST-CASP10 attached to glutathione-conjugated beads was Fas-Fc was only slightly inhibitory and a control Fc had
eluted with glutathione and incubated in protease buffer at 378C for no effect (Figure 7B). Thus, TRAIL played a key role in
various times and then analyzed by SDS±PAGE. T cell±mediated lysis of dendritic cells in this system.
(C) GST-CASP10 was prepared as in (A) and then allowed to fully
Next, we carried out direct ligand-dependent cell killingprocess (using longer incubation times for the mutant compared to
assays. We found that TRAIL induced significant den-the wild-type CASP10) to the cleaved form and then used for enzyme
dritic cell death, whereas FasL and TNFa had no mea-assays with 50 mM DEVD-AMC substrate for various times. The
release of AMC was quantitated by a fluorospectrophotometer surable effects (Figure 7C and data not shown). More-
(open symbols, wild type; filled symbols, mutant). over, dendritic cells from Pt 11 and Pt 36 underwent
significantly less apoptosis in response to TRAIL com-
pared to ALPS type I patients and healthy controls (Fig-
ure 7C). Apoptosis defects are also observed in Pt 11(TRAIL-R2) receptors, and in each case, the mutant cas-
pase interfered with death induction (Figure 5). The p35 mother and to a minor degree in the parents of Pt 36
(Figure 7C). These data suggest that the CASP10 muta-inhibitor blocked apoptosis in all cases, indicating that
the death observed was caspase dependent. By con- tions in Pt 11 and Pt 36 affect TRAIL-induced death of
dendritic cells.trast, the mutant CASP10 did not interfere with apo-
ptosis of transfected cells treated with UV irradiation or To directly demonstrate that the defective CASP10
Cell
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Figure 5. Dominant Interference with TNFR
Family Member±Induced Apoptosis by Pt 11
CASP10
293 cells were cotransfected with Fas, TNFR1,
DR3, DR4, or DR5 expression construct and
a 4-fold excess of mutant CASP10, mutant
CASP10L, or a vector alone in the presence
of a b-gal expression construct. Cells were
stained, and transfected blue cells were quanti-
tated 28 hr after transfection.
suppresses TRAIL-mediated apoptosis in dendritic cells, 11 mutant CASP10 dominantly interferes with TRAIL-
mediated apoptosis in dendritic cells.we used a retrovirus infection system to introduce the
Pt 11 CASP10 mutant into dendritic cells. Two details To determine the physiological significance of the
dendritic cell apoptosis defect, we compared frozenof our procedure are noteworthy. First, we pseudotyped
the Moloney-based vector with the vesicular stomatitis sections of lymph node from Pt 11 to lymph node tissues
from ALPS type I patients and from individuals under-virus envelope glycoprotein (VSV-G) protein (Bartz and
Vodicka, 1997), which dramatically improved the trans- going cancer staging purposes with no lymph node
involvement. Both patient 11 and ALPS type I patientsduction of freshly cultured dendritic cells over that achiev-
able with the Moloney envelope. Second, the Pt 11 exhibited increased numbers of CD31 T cells in the para-
follicular areas (Figure 7F). However, Pt 11 also exhibitedCASP10 gene was inserted upstream of an internal ribo-
some entry site (IRES) and the GFP gene, allowing us unique large accumulations of CD83-bearing dendritic
cells that were confined to the T cell areas of the lymphto monitor the efficiency of viral transduction and viral
gene expression by flow cytometry. As shown in Figure node. Dendritic cell accumulation was not observed in
several ALPS type I and control lymph node specimens7E, .70% of the cells could be infected with either the
retroviral construct carrying the CD4 gene (the control) (Figure 7F and data not shown). Thus, abnormal den-
dritic cell apoptosis is associated with overaccumula-or the vector encoding the Pt 11 mutant CASP10 (Figure
7D). When we compared the virally transduced dendritic tion of dendritic cells in the lymph node in ALPS type
II, which is not observed in ALPS type I.cells to noninfected dendritic cells, we found that TRAIL-
dependent killing was significantly reduced in cells bear-
ing the Pt 11 CASP10-expressing virus (Figure 7D). By
Discussion
contrast, dendritic cells infected with CD4-expressing
virus were killed as efficiently as uninfected cells by
Inherited mutations in Fas are currently the best known
TRAIL. These data provide direct evidence that the Pt
genetic link between apoptosis and the regulation of
lymphocyte homeostasis and immune tolerance. None-
theless, the broad range of clinical abnormalities of
lymphoproliferation and autoimmunity in humans and
mice harboring these mutations indicates that other ge-
netic or environmental factors also influence these pro-
cesses (Cohen and Eisenberg, 1991; Straus et al., 1999).
Moreover, we and others have uncovered families that
have ALPS-like disease but normal Fas and FasL genes
(Dianzani et al., 1997; Sneller et al., 1997). The cellular
and molecular bases of these abnormalities are poorly
understood and have not been identified in the mouse
models. The patients described in this report exhibit a
range of diverse autoimmune and inflammatory condi-
tions associated with disturbed immune cell homeosta-
sis. Pt 11 is an important example in this regard. Since
she was first evaluated in 1992, she has consistently
exhibited dramatic lymphoproliferation and a break-
Figure 6. Recruitment of CASP10 to Fas down in tolerance to multiple self-antigens leading to
Human 293T cells were cotransfected with expression constructs severe autoimmune complications. It was therefore sur-
for human FAS, FADD, and both isoforms of Pt 11 CASP10, as prising to find that she exhibited only a modest defect
indicated. The transfected cells were harvested and lysed 20 hr later in Fas-induced apoptosis and no genetic abnormalities
and immunoprecipitated with anti-APO-1 (anti-Fas) and sequentially
in Fas or FasL. We and others have found that diseaseprobed with anti-CASP10, anti-FAS, anti-FADD, and anti-CASP8 as
spectrum and severity usually correlate with the degreeindicated (left). The lysates were also probed with the corresponding
antibodies as shown (right). of impairment of Fas-mediated apoptosis in ALPS type
CASP10 Mutations in ALPS Type II
53
Figure 7. TRAIL-Mediated Killing of Dendritic
Cells and Immunohistochemistry Staining of
Dendritic Cells in Lymph Nodes
(A) Dendritic cells were incubated with PE-
conjugated anti-CD83, and the example of
one staining is shown.
(B) Lysis of dendritic cells by autologous
CD41 T cells at various effector:target ratios
in the presence of 10 mg/ml Fas-Fc, DR5-Fc
(TRAIL-R2-Fc), or a control Fc protein.
(C) Dendritic cells from Pt 11 and Pt 36, family
members, normal controls, and patients car-
rying Fas mutations were cultured with or
without 1 mg/ml TRAIL at 378C for 24 hr. Per-
cent cell loss was measured as described
previously.
(D) Dendritic cells infected with retrovirus ex-
pressing CD4 or Pt 11 CASP10 and unin-
fected dendritic cells were cultured with or
without 1 mg/ml TRAIL at 378C for 24 hr. Per-
cent cell loss was measured as described
previously.
(E) Dendritic cells with or without retroviral
infection were analyzed by flow cytometry for
GFP expression.
(F) Lymph node sections of Pt 11, two ALPS
patients with Fas mutations, and a normal
control were stained with CD83 for dendritic
cells, CD3 for T cell areas, and CD20 for B
cell areas.
I patients and their families (Jackson et al., 1999; Vaish- protein encoded by her mutant allele is severely defec-
tive in autoprocessing and enzymatic function. The Ptnaw et al., 1999; R. Siegel et al., unpublished data). We
can now account for the phenotype of the child and Pt 11 CASP10 can be recruited along with CASP8 into
apoptosis signaling complexes and has a dominant-36 by the discovery of inherited mutations of the CASP10
gene. In Pt 11, the allele is heterozygous, but the CASP10 interfering effect on multiple TNFR-like death receptors,
Cell
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including Fas, TNFR1, DR3, DR4, and DR5, in transfec- or environmental influences. Dominant-negative as well
as homozygous recessive mutants for CASP10 may betion assays. Pt 36 has a different mode of inheritance.
The deficiency of his mutant CASP10 is less severe, but important tools to dissect these pathways in various
immune cell types. A prime example may be dendritichomozygosity of this mutation results in a significant
impairment of apoptosis. We found certain similarities cells, for which little is known about the pathways that
govern their fate during and after immune responses.to mice and humans with Fas defects such as the over-
accumulation of lymphocytes, especially CD42CD82 T
cells and autoimmune and inflammatory disorders. Mutation Affects Autoprocessing
However, we also found an unprecedented defect in and Biochemical Function
dendritic cell apoptosis in response to TRAIL and the The inherited mutations of CASP10 that we found are
overaccumulation of dendritic cells in the lymphoid tis- both in the p17 subunit. The mutant allele in Pt 11 leads
sue from Pt 11. The combined defect in lymphocyte and to a substitution of leucine for phenylalanine at position
antigen-presenting cell apoptosis may have fundamen- 242. In Pt 36, a substitution of isoleucine for valine oc-
tal relevance to the pathogenesis of autoimmune dis- curs at position 367. The p17 subunit contains the active
ease in ALPS type II. site of the enzyme, and both mutants show impaired
caspase function. Although the crystal structure of
CASP10 has not been solved, the conservation of keyCASP10 Connects to Important Apoptosis Pathways
amino acids allowed us to make a plausible model ofThe physiological function of CASP10 is poorly under-
the CASP10 p17 based on the structures of CASP1 andstood. The gene was originally identified in the ex-
CASP3 (R. Siegel and M. J. L., unpublished results;pressed sequence tag database, and transfection assays
Walker et al., 1994; Rotonda et al., 1996). For Pt 36,verified its function as a death-inducing caspase and
the mutation alters a valine located seven amino acidsindicated that it was recruited into apoptosis pathways
downstream of the active-site QACQG motif in a regionespecially involving DR4 and DR5 (Chaudhary et al.,
that is not structurally conserved in CASP3 and CASP11997; Pan et al., 1997; Schneider et al., 1997; Vincenz
(Rotonda et al., 1996). This amino acid change may haveand Dixit, 1997). We found that the CASP10 mutations
its functional effect by virtue of its proximity to the cata-in Pt 11 and Pt 36 impair Fas-mediated apoptosis in
lytic site rather than causing a global change in the p17lymphocytes and TRAIL-induced killing in both lympho-
structure. For Pt 11, the model suggests that Leu-242cytes and dendritic cells. Moreover, transfection of the
is equivalent to Leu-164 in the first b strand of CASP3.severely defective Pt 11 CASP10 curtailed apoptosis
This position is not near the substrate-binding pocketinduction by Fas, TNFR1, DR3, DR4, and DR5. This sug-
but at an internal location of the p17 subunit. The rela-gests that CASP10 affects a signal integration point for
tively conservative nature of substitution of Phe for Leuapoptosis receptors. The downstream position of its
(i.e., both are hydrophobic) and the fact that enzymaticeffect at a point common to multiple cell death pathways
activity is not completely abolished make it unlikely thatcould account for the severe pleiotropic autoimmunity
the mutant p17 subunit is completely unfolded. Also,and inflammatory disorders and abnormal cellular ho-
Leu-242 is not sufficiently close to the interface of themeostasis in these two patients with ALPS type II.
large and small subunits or the aspartates that areThe signaling role of CASP10 vis-aÁ -vis its close homo-
cleaved during maturational processing to suggest thatlog CASP8 is not understood. The CASP8 and CASP10
it has a direct effect on processing or assembly. Rather,genes appear to be part of a gene duplication event in
we favor the notion that there is a local perturbation ofthe human CASP8/10/c-FLIP locus (2q33, interval 204.7±
the b strand containing Leu-242. This strand directly205.4). It is now evident that CASP10 in its mutant form
connects to the P1 loop that contains Arg-179, whichimpairs apoptosis in the presence of a normal CASP8
plays a crucial role in catalysis by stabilizing the P1gene. Genetic deficiencies of CASP8 have been shown
aspartic acid of the substrate, suggesting that the defectto block Fas- and TNF-induced apoptosis (Juo et al.,
in autoprocessing appears to be secondary to defective1998; Varfolomeev et al., 1998). Thus, CASP10 is unlikely
enzymatic function. Further evidence that the Pt 11 mu-to be a redundant form of CASP8. The third homolog in
tant p17 folds in an essentially correct manner is thethe locus, c-FLIP, contains multiple amino acid substitu-
fact that weak dominant-interfering effects can be ob-tions that abrogate its enzymatic function and can either
tained by expressing the mutant subunit alone (J. W.impair or enhance apoptosis by associating with apo-
and M. J. L., unpublished results). Thus, the dominantptosis signaling proteins in transfected cells (Goltsev et
interference effect results from a subtle structuralal., 1997; Irmler et al., 1997; Shu et al., 1997; Srinivasula
change that impairs catalytic activity, which apparentlyet al., 1997; Rasper et al., 1998). In a manner similar to
prevents autoprocessing after recruitment into apo-c-FLIP, the mutant CASP10 could interfere with CASP8
ptosis signaling complexes.activation. Our data show that CASP8 and CASP10 can
be corecruited by FADD to Fas (Figure 6), but the relative
contribution of either caspase to death induction by Dendritic Cell Homeostasis by Apoptosis May
Be Crucial for Immune Toleranceeach of the death receptors is not defined. In family 36,
the milder form of mutant CASP10 did not alone cause Previous investigations of autoimmunity and apoptosis
have focused almost exclusively on lymphocytes. It isa strong dominant-interfering effect as evidenced by
the minor apoptosis defect in each parent who was now evident that the turnover of antigen-presenting cells
is an important factor in the maintenance of tolerance.heterozygous and clinically normal. This could imply
that the severity of apoptosis defect may be correlated The differentiation and growth of dendritic cells have
been well studied, but little is known about their fatewith clinical phenotype independent of any other genetic
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after migration to the lymphoid organs (Banchereau and et al., 1998). Although homozygous loss-of-function mu-
tations have been rarely observed, most ALPS type ISteinman, 1998). The TNF family molecules CD40 ligand
and TRANCE produced by T cells can promote the sur- patients have Fas gene mutations that are heterozygous
and dominant interfering (Fisher et al., 1995; Rieux-Lau-vival of dendritic cells in lymphoid tissue (Anderson et
al., 1997; Wong et al., 1997). However, Jenkins and co- cat et al., 1995; Drappa et al., 1996; Bettinardi et al., 1997;
Kasahara et al., 1998). Evidence that the heterozygousworkers have observed that dendritic cells are directly
eliminated in an antigen- and T cell±dependent manner expression of the Pt 11 mutant CASP10 is sufficient for
immune pathology is provided by her mother who hassoon after an immune reaction (Ingulli et al., 1997). We
now show that activated T cells directly induced the the same heterozygous genotype and manifests high
titers of autoantibodies and apoptosis defects. Domi-death of dendritic cells. Moreover, of the three death-
inducing cytokines produced by antigen-stimulated T nant interference in ALPS reflects the fact that receptor-
mediated apoptosis requires multimeric protein±proteincells that were tested, TRAIL, but not FasL or TNF, had
the strongest apoptosis-inducing effect on dendritic cells. signaling complexes that are vulnerable to the interpo-
sition of defective proteins. Although CASP10 is ex-Moreover, CASP10 mutations impaired TRAIL-induced
dendritic cell apoptosis. Corresponding to this apopto- pressed in many tissues, it is abundant in hematopoietic
cells, which could explain why Pt 11 and Pt 36 havesis defect, we found a marked accumulation of dendritic
cells in the T cell areas of the lymph nodes in Pt 11. chiefly immunological defects (Fernandes-Alnemri et al.,
1996; Vincenz and Dixit, 1997). Dominant-interferingTaken together with the findings of Ingulli et al. (1997)
and the fact that TRAIL is produced by T cells (as well mutations of other caspases could impair selected apo-
ptosis pathways and thereby manifest themselves asas B cells and monocytes) (Marsters et al., 1996; Thomas
and Hersey, 1998; Griffith et al., 1999), the physiological disease predominantly affecting other organ systems.
disappearance of dendritic cells could be mediated by
Experimental ProceduresTRAIL. Similar lines of evidence indicate that this regula-
tory pathway is unimpaired by Fas mutations in ALPS
Detection of Patient Mutationstype I.
RT±PCR and DNA sequencing were performed as described (Fisher
Dendritic cell persistence could cause prolonged stimu- et al., 1995). Amplification primers for CASP10 cDNA were as fol-
lation of T cells and B cells (Banchereau and Steinman, lows: forward primer, 59-GAGAACCGTTTACTTCCAGAAGATTG-39;
reverse primer, 59-GCTGGAGGTTATACCCAATGATTCG-39. The1998). Usually, repeated antigen stimulation of activated
CASP10 clones were sequenced, and clones free of errors wereT cells leads to apoptosis by the propriocidal mecha-
used for experiments. Amplification primers for genomic sequencesnism (Lenardo, 1996). Our data suggest that there is a
surrounding the patient 11 CASP10 mutation site were as follows:cross-regulation in which TRAIL produced by T cells
forward primer, 59-CAGCTGTGTACAGGATGAATCGG-39; reverse
can induce dendritic cell apoptosis. However, in ALPS primer, 59-CATCTTTATGGGTTCCTTGTCTGTC-39. A 76 bp product
type II, both T cells and dendritic cells have impaired amplified from genomic DNA was digested with Stu I followed by
electrophoresis on 3% agarose gels. Amplification primers for geno-apoptosis responses and accumulate in T zones where
mic sequences surrounding the patient 36 CASP10 mutation sitethe lingering dendritic cells could induce responses that
were as follows: forward primer, 59-ACAGCCCTGCAGTGCCCTdo not normally take place. The combined apoptosis
AGA-39; reverse primer, 59-ACTGTCCTGCAGGGAAGTGGG-39. Thedefects in two interacting cell types (i.e., dendritic cells
frequency of patient 36 CASP10 mutation was analyzed by SSCP
and T cells) may be responsible for the disease pheno- analysis of amplified genomic DNA samples.
type in ALPS type II.
Cell Culture and Apoptosis Assay
Human PBLs were stimulated with PHA and then IL-2 as described
(Fisher et al., 1995). Dendritic cells were cultured as described pre-Both Dominant and Recessive Mutations May Produce
viously (Sallusto and Lanzavecchia, 1994). Apoptosis induced by
Disease Due to Apoptosis Dysfunction anti-Fas (CH11) and anti-CD3 (64.1) were analyzed as described
Pt 11 and Pt 36 have been developmentally normal thus (Fisher et al., 1995). A soluble TRAIL tagged at the N terminus with
a leucine zipper motif is a generous gift from Dr. David Lynch atfar and manifested disease primarily in the postnatal
Immunex (Walczak et al., 1999). To analyze TRAIL-mediated apo-period. Pt 36 has inherited two identical defective alleles
ptosis, T cells or dendritic cells were incubated in culture mediumfrom unaffected heterozygous parents in the manner of
with or without 1 mg/ml TRAIL at 378C for 24 hr, and cell loss induceda classic Mendelian recessive trait. The Pt 36 CASP10
by TRAIL was calculated as described (Fisher et al., 1995).
mutation is a G to A mutation that occurs at a CpG
dinucleotide, which is a known ªhot spotº for C to T Transfection
MCF7, HeLa, and 293 cells were transfected with various constructstransitions involved in human diseases (Kotze et al.,
plus pcDNA3-LacZ by the Superfect method (Qiagen). Twenty-four1997). An increased allele frequency in the Ashkenazi
hours after transfection, the cells were fixed with PBS containingJewish population was ruled out in our screening. Homo-
2% formaldehyde and 0.2% glutaraldehyde at room temperature forzygosity in Pt 36 may reflect common ancestry of mother
5 min. The cells were then stained by incubation in PBS containing 1
36 and father 36, though they are unaware of any con- mg/ml X-gal, 5 mM ferricyanide, 5 mM ferrocyanide, 2 mM MgCl2,
sanguinity. 0.02% NP-40, and 0.01% SDS at 378C. Live and dead cells stained
with blue color were scored under a microscope.The fact that Pt 11 had severe disease with a mutation
that was heterozygous and strongly dominant interfering
Expression of GST-CASP10 and Protease Assayis significant. The results of experiments with null de-
The CASP10 protease domain was cloned into pGEX-4T.1 and ex-fects for individual caspases in mice reveal either sur-
pressed in BL21plyss, and the GST-CASP10 fusion protein was
prisingly little apoptosis phenotype or perinatal lethality induced by 0.1 mM IPTG. Bacteria from a 30 ml culture were resus-
(Li et al., 1995; Kuida et al., 1996, 1998; Ghayur et al., pended in 500 ml cell extraction buffer (25 mM HEPES [pH 7.5],
0.1% CHAPS, 5 mM EDTA, and 2 mM DTT) and lysed by freezing1997; Hakem et al., 1998; Varfolomeev et al., 1998; Wang
Cell
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and thawing, followed by sonication. The fusion proteins from 50 percentage cell lysis was quantitated as described (Wang and Len-
ardo, 1997).ml bacterial lysates were purified by glutathione Sepharose (Phar-
macia) and used for SDS±PAGE or protease assay. To assay prote-
ase activity, CASP10 extracts were added to 200 ml protease buffer Immunohistochemistry Staining
(30 mM HEPES [pH 7.4], 10% sucrose, 1 mM CaCl2, 5 mM DTT) Sections of frozen lymph node tissues were stained with anti-CD83
containing 50 mM Asp-Glu-Val-Asp-AMC (DEVD-AMC) or 50 mM Tyr- (Immunotech), anti-CD3 (Becton Dickinson), or anti-CD20 (Dako)
Val-Ala-Asp-MCA (YVAD-MCA) and incubated at room temperature. followed by biotinylated secondary antibody and HRP-conjugated
The released MCA were measured by excitation at 390 nM and streptavidin (Vector). The sections were then developed with the
absorbance at 460 nM in a fluorospectrophotometer (Tecan). Bacte- substrate kit containing DAB/metal and peroxidase substrate kit
rial GST-CASP10 fusion proteins were purified on glutathione aga- (Pierce) for CD20 and CD83 staining or the ABC immunoperoxidase
rose beads and eluted with 5 mM glutathione. The fusion proteins technique (Lim et al., 1998) for CD3 staining. The cell nuclei were
were quantitated using Coomassie blue method (Biorad), and 2 mg counterstained with hematoxylin.
of each fusion protein was used for 200 ml caspase reactions. For
Km determination, varying amounts of DEVD-AMC were used, and
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